We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Flat As Market Gains: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed the most recent trading day at $6.41, making no change from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%.
Coming into today, shares of the vaccine maker had gained 14.46% in the past month. In that same time, the Medical sector lost 2.95%, while the S&P 500 lost 0.47%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. The company is scheduled to release its earnings on May 8, 2025. It is anticipated that the company will report an EPS of $0.19, marking a 118.1% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $71.84 million, indicating a 23.47% decline compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.63 per share and revenue of $536.24 million, indicating changes of +151.22% and -21.39%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 694.59% higher. At present, Novavax boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Novavax currently has a Forward P/E ratio of 10.2. For comparison, its industry has an average Forward P/E of 17.32, which means Novavax is trading at a discount to the group.
Also, we should mention that NVAX has a PEG ratio of 0.24. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.34.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 84, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Flat As Market Gains: What You Should Know
Novavax (NVAX - Free Report) closed the most recent trading day at $6.41, making no change from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%.
Coming into today, shares of the vaccine maker had gained 14.46% in the past month. In that same time, the Medical sector lost 2.95%, while the S&P 500 lost 0.47%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. The company is scheduled to release its earnings on May 8, 2025. It is anticipated that the company will report an EPS of $0.19, marking a 118.1% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $71.84 million, indicating a 23.47% decline compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.63 per share and revenue of $536.24 million, indicating changes of +151.22% and -21.39%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 694.59% higher. At present, Novavax boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Novavax currently has a Forward P/E ratio of 10.2. For comparison, its industry has an average Forward P/E of 17.32, which means Novavax is trading at a discount to the group.
Also, we should mention that NVAX has a PEG ratio of 0.24. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.34.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 84, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.